Another year has passed and Giaconda has survived the worst of...

Another year has passed and Giaconda has survived the worst of the GFC thanks to directors financing the pass year and $500,000.00 from Redhill Biopharma.

As in my previous posts Giaconda has turned a significant corner with future development of the three main drugs. MYOCONDA, HELICONDA and PICOCONDA. The company will be developing these 3 drugs in the final stage is called is called Redhill Biopharma which is based in Israel.

Redhill LEAD product will be Myoconda (1) and according the CEO of Giaconda they are going ?full steam ahead? and ?have already started testing?. According to the CEO of Giaconda Myoconda will be approved in 18 months to 2 years. This should be the start of big things for Giaconda. As Giaconda business plan was to sell the drugs Intellectual Property (IP) and retain a royalty.

Other questions asked were about ?any new drugs in development?? Apparently with drug development other cures can/could be found. Such as with the development of Ibaconda the base drug is ?Olsalazine is an anti-inflammatory? (2). (This drug Olsalazine could be treating IBS in the future) and Ibaconda could be treating some other disease for example such as bowel cancer??.don?t know what?. (Don?t get your hopes up with Ibaconda it?s many, many, and many???.. years away from being approved)

Also Giaconda will be getting a Twitter account and a Facebook page. Seems kind of silly but this is the future for marketing and keeping interest in the drug development on Myoconda and future drugs. One gentleman at the AGM stated that a NSW Government Dep?t has 100,000 followers on Twitter and many drug companies are utilising this new FREE media (so not so silly).

REDHILL BIOPHARMA
Redhill has raised 10 Million Dollars from Private Investors (3) Originally Redhill only required to raise 3 Million Dollars (I?m assuming that it is in US$). Redhill could be listed on the Israel stock exchange in the future according to many websites ?we are examining the possibility of an IPO on the Tel Aviv Stock Exchange? (4) If listed I don?t think much will change with Giaconda.

The Future for Giaconda
This company has been a disappointment in the pass with a dwindling share price. But with Directors willing to support the company with financing the company now has strong future.

I personally would like to see more announcements from Giaconda on the actual start date of the clinical trial and what Redhill are actually doing! If this happens I feel that there will be more confidence with investors and share price will increase. Last update on a drug was 9/7/2008.

Giaconda shares are tightly held and very few shares are traded weekly /monthly. As stated before Giaconda top 20 own approx 85% (In the top 5 of the ASX of tightly held stock). Since the shares are so tightly held share price could jump very high very quickly as it happened this week (up 30% on low volume)

When Myoconda is approved the share price will not be under a $1.00 due to a very tight a shareholding.

If investing with Giaconda it is a long term investment.


Wally.........

1. http://technews.tmcnet.com/news/2010/11/04/5117524.htm
(Lead Product 5th Parra graph)
2. http://www.giacondalimited.com/pages/products/iba_conda.html (5th Paragraph)

3. http://www.vcaonline.com/news/news.asp?ID=2010110804 ( Investment- Headline)

4. http://au.finance.yahoo.com/news/RedHill-Biopharma-Raises-35M-bw-2252113904.html?x=0 (5th Paragraph)